

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Chaim GILON et al

Serial No.:

10/508,959

Filed:

August 16, 2005

For:

HISTONE CONJUGATES AND USES THEREOF

Attorney

Docket: 28557

Group Art Unit: 1656

Examiner:

DESAI, ANAND U

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin O. Mayruka

Martin D. Moynihan

Registration No. 40,338

Dated: October 26, 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Under the Reprovork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MABELLA	ABELIANDE WORK REDUCTION ACT OF 1999, the persons are required to respond to a cone				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				О	Application Number 10/508,959 Filing Date August 16, 2005			
				OSURE			2005	
				LICANT	First Named Inventor	Chann Gizor va		
				ssary)	Art Unit			
					Examiner Name	DESAI, AN	NAND U	
Sheet		1	of	3	Attorney Docket Number	28557		
				U.S. PATENT	DOCUMENTS			
Examiner Initials*	Cite No.			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<u></u>	Number-Kind Code ^{2 (if kno}					- igares i ippea	
	1	US-6,262,264		07-17-2001	Buck et al.			
	2	US-5,607,691		03-04-1997	Hale et al.			
	3	US-5,994,109		11-30-1999	Woo et al.			
	4	US-6,444,421		09-03-2002	Chung			
	5	US-6,369,030		04-09-2002	Cole et al.			
	6	US-5,807,999		09-15-1998	Kohtz			
	7	US-4,415,553		11-15-1983	Zhabilov et al	l .		
	8	US-5,939,070		08-17-1999	Johnson et al			
	9	US-5,427,958		06-27-1995	Plaue et al.			
	10	US-2003/0170615		09-11-2003	Ustav et al.			
	11	US-4,476,301		10-09-1984	Imbach et al.			
	12	US-5,539,082		07-23-1996	Nielsen et al.	·		
	13	US-5,625,050		04-29-1997	Beaton et al.			
	14	US-5,714,331		02-03-1998	Buchardt et a	l		
	15	US-5,719,262		02-17-1998	Buchardt et a	l		
	16	US-5,932,447		08-03-1999	Siegall			
	17	US-6,303,374		10-16-2001	Zhang et al.			
	18	US-6,270,098		08-07-2001	Heyring et al	•		

		FOREIGN	I PATENT DOC	UMENTS		
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ . Number ⁴ . Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant FiguresAppear	
	19	PCT WO 98/09985	03-12-1998	Eisenbach-Schwartz et al.		
	20 PCT WO 98/07859 02-26-1998 Merberg et al.		Merberg et al.			
	21	PCT WO 98/05635	02-12-1998 Owen et al.			L
Examine Signatur	1			Date Considered		<u> </u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

		perwork Reduction Act of 1995, no	persons are required to respon		iplete if Known	control number.				
Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number 10/508,959						
				Filing Date	August 16, 2005					
				First Named Inventor Chaim GILON et al						
				Group Art Unit	1656					
	•	•		Examiner Name	DESAI, ANAND U					
Sheet	2	of	3	Attorney Docket Number						
					28557					
Examiner	Cite	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the								
Initials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
	22	Booth et al. "The Use o	Booth et al. "The Use of A 'Universal' Yeast Expression Vector to Produce An							
		Antigenic Protein of Mycobacterium Leprae", Immunology Letters, 19: 65-70, 1988.								
	23	Gardella et al. "Expression of Human Parathyroid Hormone-(1-84) in Escherichia Coli as A Factor X-Cleavable Fusion Protein", The Journal of Biological Chemistry,								
			gical Chemistry,							
	24		265(26): 15854-15859, 1990. Brogli et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate							
	27	Carboxylase Small Sub								
		843, 1984.	and Gone in Translet	inica i iani cens , seren	ce, 22 i . 050					
•	25	Balicki et al. "Structure and Function Correlation in Histone H2A Peptide-Mediated								
		Gene Transfer", Proc. Natl. Acad. Sci. USA, 99(11): 7467-7471, 2002. P.7469,								
		Col.2, Lines 9-11.								
	26	Théodore et al. "Intraneuronal Delivery of Protein Kinase C Pseudosubstrate Leads to Growth Cone Collaps", The Journal of Neuroscience, 15(11): 7158-7167, 1995.								
	27	Growth Cone Collaps", The Journal of Neuroscience, 15(11): 7158-7167, 1995. Tudela et al. "TGF-β3 Is Required for the Adhesion and Intercalation of Medial Edge								
	-	Epithelial Cells During Palate Fusion", International Journal of Developmental								
		Biology, 46(3): 333-336, 2002.								
	28	Boussif et al. "A Versatile Vector for Gene and Oligonucleotide Transfer Into Cells in Culture and In Vivo: Polyethylenimine", Proc. Natl. Acad. Sci. USA, 92: 7297-								
		in Culture and In Vivo:	SA, 92: 7297-							
100	120	7301, 1995.	'- D-1' NA 1'	. 11 . 1						
	29	Cotton et al. "Transferr Leukemic Cells: Stimul								
		or Modulate Transferring								
		4037, 1990.	, recorptor Bevels , i	Too. Mail. Mead. Sel. OS	71, 07. 4055-					
	30	Johnson-Saliba et al. "I	Distinct Importin Rec	ognition Properties of H	istones and					
		Chromatin Assembly F	actors", FEBS Letter	s, 467: 167-174, 2000.						
	31			calisation Signals of the						
	122			nistry, 81(2): 333-346, 20						
	32	DNA", Human Gene Trans		Cells Using Histone-Cor	idensed Plasmid					
	33	Böttger et al "Acid Nu	clear Extracts as Med	liators of Gene Transfer	and Evpression"	·				
		Biochimica et Biophysi	ca Acta, 1395(1): 78	-87, 1998. Abstract.	and Expression ,					
	34	Chen et al. "Galactosyla	ated Histone-Mediate	ed Gene Transfer and Ex	pression",					
		Human Gene Therapy,	5(4): 429-435, 1994.	Abstract.						
	35			Acids Stimulate the Upta						
		by Tumor Cells in Cult	ure", Science, 150(36	595): 501-503, 1965. Abs	stract.					

^{*} considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/508,959 INFORMATION DISCLOSURE Filing Date August 16, 2005 STATEMENT BY APPLICANT First Named Inventor Chaim GILON et al Group Art Unit (use as many sheets as necessary) 1656 Examiner Name DESAI, ANAND U Sheet 3 Attorney Docket Number of 3 28557 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), No.1 T^2 Initials publisher, city and/or country where published. 36 Brix et al. "Extracellularly Occurring Histone H1 Mediates the Binding of Thyroglobulin to the Cell Surface of Mouse Macrophages", Journal of Clinical Investigations, 102(2): 283-293, 1998. 37 Murphy et al. "Kinetics of histone Endocytosis in Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, 257(14): 1695-1701, 1982. 38 Higashijima et al. "Regulation of G(i) and G(o) by Mastoparan, Related Amphiphilic Peptides, and Hydrophobic Amines. Mechanism and Structural Determinants of Activity", The Journal of Biological Chemistry, 265(24): 14176-14186, 1990. Schmid et al. "ATP Is Required for Receptor-Mediated Endocytosis in Intact Cells", 39 The Journal of Cell Biology, 111(6/Pt.1): 2307-2318, 1990. 40 Okamoto et al. "Cholesterol Oxidation Switches the Internalization Pathway of Endothelin Receptor Type A From Caveolae to Clathrin-Coated Pits in Chinese Hamster Ovary Cells", The Journal of Biological Chemistry, 275(9): 6439-6440, Adam et al. "Nuclear Protein Import in Permeabilized Mammalian Cells Requires 41 Soluble Cytoplasmic Factors", The Journal of Cell Biology, 111: 807-816, 1990. 42 Adam et al. "Cytosolic Proteins That Specifically Bind Nuclear Location Signals Are Receptors for Nuclear Import", Cell, 66(5): 837-847, 1991. Abstract. 43 Anderson et al. "Protocytosis: Sequestration and Transport of Small Molecules by Caveolae", Science (Perspectives), 255: 410-411, 1998. 44 Suzuki et al. "Possible Existence of Common Internalization Mechanisms Among Arginine-Rich Peptides", The Journal of Biological Chemistry, 277(4): 2437-2443, 2002. 45 Futaki et al. "Arginine-Rich Peptides. An Abundant Source of Membrane-Permeable Peptides Having Potential as Carriers for Intracellular Protein Delivery", The Journal of Biological Chemistry, 276(8): 5836-5840, 2001. Polyakov et al. "Novel-TAT-Peptide Chelates for Direct Transduction of 46 Technetium-99m and Rhenium Into Human Cells for Imaging and Radiotherapy", Bioconjugate Chemistry, 11(6): 762-771, 2000. Abstract. 47 Plank et al. "Application of Membrane-Active Peptides for Drug and Gene Delivery Across Cellular Membranes", Advanced Drug Delivery Reviews, 34: 21-35, 1998. Efthymiadis et al. "The HIV-1 Tat Nuclear Localization Sequence Confers Novel Nuclear Import Properties", The Journal of Biological Chemistry, 273(3): 1623-1628,

Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional).

2. Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.